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Abstract 
Cancer stem cells (CSCs) are believed to be a principal cellular source for tumour progression and 
therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer 
cells. Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through 
changes at the genetic, epigenetic and micro-environment levels. Therefore, therapeutic strategies 
targeting CSCs hold great potential as an avenue for cancer treatment. Aptamers or “chemical 
antibodies” are a group of single-stranded nucleic acid (DNA or RNA) oligonucleotides with 
distinctive properties such as smaller size, lower toxicity and less immunogenicity compared to 
conventional antibodies. They have been frequently used to deliver therapeutic payloads to cancer 
cells and have achieved encouraging anti-tumour effects. This review discusses progress in CSC 
evolution theory and the role of aptamers to target CSCs for cancer treatment. Challenges of 
aptamer-mediated CSC targeting approaches are also discussed. 
Key words: aptamers; CSCs; cancer; drug resistance; antibodies; nanoparticles. 
Introduction 
Despite significant progresses in therapy, 
effective cancer treatment still remains an unmet 
clinical need. This is mainly due to the failure of 
present treatments to eradicate a subset of rare but 
important cells known as cancer stem cells (CSCs) [1]. 
CSCs have similar properties to adult stem cells such 
as the ability for unlimited self-renewal and 
differentiation and are believed to be a major source 
of cancer initiation, progression and drug resistance 
[2]. It is now understood that standard cancer 
treatments only eliminate rapidly proliferating cancer 
cells (non-CSCs), whereas the relatively quiescent 
CSCs can escape cell death and even be enriched in 
the remaining or recurrent tumour. These CSCs are 
thought to be the “root” of cancer relapse and 
metastasis. Thus, developing therapeutic strategies 
that not only kill non-CSC, but also eliminate CSCs 
has potential for achieving better treatment outcomes.  
Over the past few years, many agents and 
strategies targeting CSCs have been developed [3-5]. 
However, successful penetration and accumulation of 
therapeutic agents into the tumour core particularly to 
CSCs is extremely difficult due to complicated drug 
resistance mechanisms. In addition, current anti-CSC 
reagents face numerous obstacles such as poor 
retention and bioavailability and strong 
immunogenicity and high toxicity which greatly 
hinders their clinical application [6, 7]. Aptamers are 
short single-stranded oligonucleotides that are 
selected from pools of random nucleic acid 
oligonucleotides by a systematic evolution of ligands 
by exponential enrichment (SELEX) (Fig. 1) [8, 9]. 
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Aptamers can fold into unique tertiary structures and 
bind to their cognate targets with high affinity and 
specificity, hence the term “chemical antibodies” [10]. 
Importantly, aptamers exhibit multiple characteristics 
that are superior to conventional antibodies such as 
low toxicity and non-immunogenicity (Table 1) [10]. 
Furthermore, the smaller size of aptamers greatly 
facilitates their diffusion and penetration into tumour 
cores favouring the transport of therapeutic agents 
and nanoparticles (NPs) to their targets [11]. These 
properties make aptamers a prominent vehicle to 
accomplish specific drug delivery to cancer cells. 
Currently, a variety of aptamers targeting specific 
CSC surface markers have been developed and 
aptamer-based nano-medicine systems have achieved 
excellent anti-CSCs effects in preclinical studies 
[12-16]. In this review we provide readers with an 
understanding of recent developments on the subject 
of CSC evolution and discuss aptamers that target 
CSCs and their potential use for cancer treatment.  
Table 1. Comparison of aptamers and conventional antibodies 
 Aptamers Antibodies 
Targets Wider range (nucleic acids, 
metal ions, organic 
molecules, amino acids, 
antibiotics, proteins, virus, 
whole cells, organisms) 
Mostly larger molecules 
Size 10~25 kD  50~100 kD 
Production 
process 
In vitro selection  In vivo selection  
Toxicity 
Immunogenicity  
Very low 
No or minimal  
Relatively higher 
Relatively stronger 
Cost of 
production 
Cost-effective Expensive 
Modification Easy to modify with 
imaging agents or 
therapeutic components 
Difficult to modify 
Stability Stable in a harsh tumour 
micro-environment Lower stability in physiological environments 
Inter-batch 
variability 
Low Significant 
 
 
Figure 1. A schematic illustration of the SELEX method for aptamer selection. A random oligonucleotide library consisting of a large array of different sequence 
motifs (in the range of 1014-15) is designed. Two primer-binding sequences on both ends (5’ and 3’) of the randomized sequences allow for PCR amplification. The 
oligonucleotide library is then incubated with a pool of targets (such as proteins, nucleic acids or whole cells) under appropriate buffer and temperature conditions. 
Following stringent washing steps, a very small fraction of sequences with high binding affinities and specificities towards the target protein is separated from unbound 
or weakly bound sequences via various partitioning strategies. The tight binders are then eluted by dissociating the DNA or RNA-target complex and amplified by 
PCR to enrich into a new oligonucleotide pool which is then subjected to the next round of SELEX. This process is typically repeated for 10-15 rounds to enrich the 
sequences binding to the corresponding targets with highest affinity and specificity. To enhance the enrichment efficiency and specificity of aptamers, the stringency 
of the selection conditions is progressively increased in the later rounds through using effective binding competitors or decreasing the amount of proteins. The most 
promising sequences are randomly cloned and sequenced to obtain individual aptamers that are specifically involved in target recognition. 
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Evolution of models of cancer stem cell 
behaviour 
The discovery of phenotypically distinct CSC 
pools with an extraordinary capacity to sustain 
long-term clonal growth and re-populate competitive 
sub-clones to survive therapies represents a rational 
explanation for the functional diversity of tumour 
cells and treatment resistance [17]. It is now believed 
that CSC evolution involves a dynamic equilibrium 
that requires both CSCs and the conventional clonal 
model acting in concert (Fig. 2A-B) [17]. Although 
CSCs can occasionally be replaced by normal stem 
cells [18], oncogenic mutations and epigenetic 
changes in CSCs at the early phase of tumour growth 
render these special clones less likely to be substituted 
by wild-type stem cells. Interestingly, the competition 
between normal stem cells and primary CSCs is 
closely dependent on the tumour microenvironment. 
For example, P53 mutated CSCs had similar 
proliferative capacities to wild-type normal stem cells 
in physiological conditions while they exhibited 
stronger progression than wild-type stem cells in 
inflamed intestine [18]. The combinatory effects of 
diverse advantageous mutations, epigenetic 
reprograming and micro- environmental factors 
results in multiple pools of rare primary CSCs with 
various self-renewal capabilities and variable 
aggressive properties. Within these pools there may 
be initiating, quiescent or slow cycling CSCs [19]. 
Indeed, distinct CSCs with diverse phenotypes and 
functions have been identified in leukemia and other 
solid organ tumours [7, 20-22]. 
As tumours evolve and progress, additional 
advantageous mutations and micro-environmental 
pressures (e.g., as a result of cancer therapies) may 
impair the maturation process and cause competitions 
among diverse CSCs, leading to the expansion of 
increasingly competitive CSCs with even higher 
self-renewal capacity and more aggressive 
phenotypes [23]. When tumours progress to an 
advanced stage, the frequency of competitive CSCs 
with superior fitness will increase to become 
functionally and phenotypically homogeneous [23]. In 
this process, metastatic CSCs may emerge at the apex 
of tumour evolution upon overcoming other 
competing CSCs with less pioneering capacity. 
Interestingly, the last step of tumour evolution is 
always accompanied by a reduction of CSC expansion 
when the patient is in remission or ultimately 
succumbs to the tumour. This suggests that 
uncontrolled CSC expansion eventually leads to their 
destruction and is referred to as “CSC overshot”, a 
phenomenon similar to what occurs in ecosystems 
when the number of a species exceeds the maximum 
bearing capacity of their surroundings [24] (Fig. 2B). It 
is now understood that the number of CSCs within 
the same tumour dynamically changes during the 
entire malignant process, developing along a steep 
hierarchy in the primary stage consisting of a small 
number of heterogeneous CSCs and a larger number 
of differentiated non-CSCs, towards a hierarchy 
containing continually increasing proportions of 
CSCs, and constant progress to a very shallow 
hierarchy in the metastatic stage where the proportion 
of CSCs reach a plateau [23, 24] (Fig. 2B). Thus, CSC 
heterogeneity may apply more correctly to the early- 
rather than the more advanced stage of tumour 
development in which dominant clones probably 
drive tumour growth. 
The complexity of tumour evolution is further 
reflected by the plastic inter-conversion between 
CSCs and non-CSCs. This is thought to result from a 
combination of micro-environmental pressure, 
genetic mutations and epigenetic reprogramming [25, 
26-28] (Fig. 2B). Interestingly, the relationship 
between CSCs and the microenvironment is 
bidirectional in that the niche can determine the fate 
of CSCs and conversely, CSCs can alter the local 
environment. Indeed, glioblastoma (GBM) CSCs have 
been found to secret VEGF to stimulate the expansion 
of vasculature, whereas tumour endothelial cells may 
secret nitric oxide that can activate Notch signalling in 
glioma cells, a key regulatory mechanism for CSCs 
[29]. Surprisingly, some studies even demonstrate 
functional and phenotypic inter-conversions between 
different subsets of CSCs [29]. 
Taken together, the selective survival advantage 
of quiescent CSCs and expansion of aggressive CSCs 
upon several cycles of chemotherapy results in a 
relative increase in the CSC population in the residual 
tumour. Besides, conversion of non-CSCs to CSCs 
following targeted CSC therapies may be partially 
responsible for the resurgence of CSCs. Therefore, a 
combination of CSC-targeting approaches and 
therapeutic strategies that can ablate epigenetic or 
micro-environmental factors responsible for the 
transformation of progenitor cells into CSCs may 
open new avenues for inhibiting cancer recurrence 
(Fig. 2C). 
Aptamer-mediated drug transport to 
cancer stem cells (CSCs)  
Most CSCs have been found to reside in the 
tumour center far away from tumour blood vessels. 
This means that therapeutic agents have to cross 
various biological obstacles in order to reach their 
targets. These obstacles may include leaky 
blood/lymphatic vessels, extracellular matrix (ECM) 
in which therapeutic agents may accumulate and 
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tumour cell membranes that the agents have to 
penetrate through before reaching the peri-nuclear 
regions of CSCs [30]. These barriers may lead to 
impaired drug uptake, excessive drug degradation 
and short drug circulation within the tumour [24, 31]. 
In addition, agents without cancer targeting moieties 
may indiscriminately diffuse into both normal and 
tumour blood vessels leading to unwanted side effects 
[31]. Therefore, effective delivery approaches are 
needed to not only specifically transport therapeutic 
agents to CSCs but also to maintain their 
bioavailability and pharmacokinetics in blood. In this 
perspective, active targeting strategies which depend 
both on the enhanced permeability and retention 
(EPR) effect and aptamer-guided specific targeting 
have been explored. 
 
 
Figure 2. Schematic illustration of the clonal evolution and dynamic plastic CSC model. A. Clonal evolution is a non-hierarchical model that acquires the successive 
accumulation of mutations to confer special clones with a competitive growth advantage under the pressures of cancer therapy, resulting in the expansion of surviving 
homogeneous sub-clones. B. The integration of clonal and the dynamic plastic CSC model. Primary mutations in progenitor cells endow them with stem cell 
properties to become initiating CSCs. Some of the mutated cells can remain quiescent and become metastatic CSCs, while other initiating CSCs transform to 
aggressive CSCs that eventually give rise to competitive metastatic CSCs upon serial mutations. The CSC populations gradually expand and dominate tumour sites 
although they eventually crash down upon cancer remission. Bio-directional plastic inter-conversion can occur between different CSCs or between the CSCs and 
non-CSCs, leading to complicated tumour heterogeneity. C. Therapeutic strategies targeting CSCs. Current chemotherapy can only kill rapidly dividing differentiated 
cancer cells in the tumour bulk but resistant CSCs are largely spared. The combination of traditional chemotherapy with CSC-targeted therapy is more likely to 
destroy non-CSCs and CSCs with better therapeutic outcomes. As residual non-CSCs can still convert to CSCs resulting in tumour relapse, and since tumour micro- 
environmental or epigenetic factors also contribute to the conversion of non-CSCs to CSCs, effective cancer therapy may require multiple approaches targeting 
CSCs, non-CSCs, and their dynamic conversion. 
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Aptamers are 15-20 times smaller than 
antibodies and possess a range of advantages over 
conventional antibodies. Hence they have now 
emerged as a class of ideal drug delivery agents. 
Studies have shown that aptamer-based therapeutic 
drug delivery offers excellent tissue-penetrating 
properties and improved access of cytotoxic agents to 
CSCs within hypoxic regions [10]. Incorporation of 
aptamers on the surface of drug-carrying NPs can 
greatly enhance the efficiency of receptor-mediated 
endocytosis since the non-covalent binding of 
aptamers to their cognate receptors allows rapid 
dissociation of the aptamer-receptor complexes and 
recycling of the receptors to the cell surface in an 
intact configuration upon aptamer internalization [12, 
14]. In addition, the conjugation of NPs with aptamers 
can augment the entrance and localization of NPs into 
the acidic environment of endosomes or lysosomes 
[32]. Since drugs release more readily from NP 
carriers in the acidic microenvironment than in the 
neutral condition, endosomal localization of 
aptamer-tailed NPs allows more effective release of 
functional free drug to the cytoplasm [33]. For 
example, a CD30 aptamer previously loaded with 
Doxorubicin (Dox) and surface engineered with a 
gold nanosphere (HAuNS) was used to generate a 
NPs-based chemotherapeutic system termed 
“apt-HAuNS-Dox”; this complex was able to rapidly 
release 80% of coupled Dox within 2 h at pH 5.0 while 
only 55% of Dox could be released from HAuNS-Dox 
without aptamer conjugation [34, 35] Furthermore, 
pH-triggered drug delivery systems such as 
aptamer-single-walled carbon nanotubes [35] and 
endosomal escape units like PEG-charge-conversion 
polymers allow endosomal membrane destabilization 
[33] and greatly minimizes the adhesion of NPs to 
endosomes leading to more effective endosomal 
escape of the therapeutic cargo. 
Indeed, aptamer-tagged macromolecules were 
recently found to effectively enter and retained in 
tumours [36]. For example, an aptamer against 
EpCAM (a commonly used CSC marker) 
demonstrated 8-fold higher concentration in 
endosomes than EpCAM antibody [35]. Additional 
studies showed that EpCAM aptamers penetrated 
into the center of tumour spheres within 30-240 min 
and remained in the tumour cores for at least 26 h 
whereas the signal of EpCAM antibody was barely 
detectable after 4 h of incubation [36]. Besides, 
PEGylated aptamers could retain in animal tumours 
for more than 26 h, 4.3-fold longer than what could be 
achieved by an antibody. PEGylated aptamers also 
showed stronger tissue penetration capacity than 
antibody in that PEGylated aptamers were detectable 
150-200 μm away from the blood vessels of tumour 
tissues whereas the antibody was mainly distributed 
near blood vessels [36]. In a very recent study, 
aptamer-anchored polymersome vesicles exhibited 
favourable tumour penetration ability in both 3D 
tumour spheroids and tumour-bearing mice; these 
vesicles were shown to selectively accumulate Dox to 
tumour sites leading to decreased systemic toxicity 
and significant suppression of breast cancer in vivo 
[37]. These encouraging results suggest that aptamers 
can be used as promising escorting tools to target 
CSCs.  
Aptamer-guided drug delivery to CSCs  
Selectively delivering cytotoxic agents using 
aptamers to CSCs has been explored in cancer therapy 
and various aptamers that can specifically and 
effectively target CSC surface markers have been 
developed (Table. 2) (12-16; 38-46). These aptamer 
moieties are able to deliver free drugs or drug-loaded 
NPs to CSCs with negligible harmful effects to normal 
cells (Table. 3). Upon entering into tumour tissues by 
the EPR effect, the aptamer complex may cross the 
barrier of ECM interstitia without undergoing 
degradation and are selectively internalized into CSCs 
via receptor-mediated endocytosis, an important 
mechanism capable of bypassing ATP-binding 
cassette transporters (Fig. 3). 
 
Table 2. Aptamers targeting surface markers of CSCs 
Aptamers (apt) Targets Binding affinity (Kd) Cell lines tested Refs 
EpDT3/EP166/SYL3C (RNA) EpCAM 6 nM-67 nM HT29/Hep3B/MCF7 
/HepG2/KatoIII/MDA-MB-231 
[12, 16, 38, 39] 
 
A15/B19 (RNA) CD133 34-145 nM HT29/Hep3B [15] 
TA1/TA6 (DNA) 
/Apt1/MS03(RNA)  
CD44 21.5-285 nM SKOV3/IGROV/A2780/A549/MCF7/MCF10A [39-42] 
Kit-129/Apt1-4 (DNA) CD117 7.1-36.2 nM BJAB/HEL [43, 44] 
A12/35 (RNA) ABCG-2 16.7 nM MCF-7/MDA-MB23 [45] 
A1/A4 (DNA) GBM CSCs 0.27-3.8 nM CD133+ GBM cells [13] 
CSC13/17/22 (RNA) Prostate CSCs 2.2-31.3 nM DU145/PC3/LNCaP [14] 
A549: lung cancer cell line; BJAB: Burkitt lymphoma B cell line; DU145, PC3, LNCaP: prostate cancer cell lines; HEL: human erythroleukemia cell lines; Hep3B, HepG2: liver 
cancer cell lines; HT29: colon cancer cell lines; KatoIII: gastric cancer cell line; MCF7, MDA-MB-231: breast cancer cell lines; SKOV3, IGROV, A2780: ovarian cancer cell lines; 
Binding Kd is defined as the concentration of aptamer at which 50% of the cell receptor sites are occupied. 
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Table 3. Aptamer-mediated delivery of therapeutic agents to CSCs 
Aptamers (DNA or RNA) Targets Cytotoxic agents Delivery vehicle Anti-CSCs effect Refs 
Apt4 (DNA) CD117 MTX Apt4 Induce apoptosis in AML CSCs in vitro and in vivo 44 
EpDT3 (RNA) EpCAM Dox EpDT3 Inhibit proliferation of retinoblastoma CSCs in vitro 46 
Anti-EpCAM (RNA) EpCAM Dox PLGA-PEG NPs Induce significant cytotoxicity to breast CSCs in vitro 48  
Anti-EpCAM (RNA) EpCAM Dox PLGA-PEG NPs Induce cytotoxicity to lung cancer CSCs in vitro, inhibit tumour 
growth in vivo 49  
Anti-EpCAM (RNA) EpCAM Curcumin PLGA-lecithin-PEG Induce substantial cytotoxicity to colon CSCs in vitro 37 
Anti-EpCAM (RNA) EpCAM Nutlin-3a PLGA-QD Induce cytotoxicity to breast and ovarian CSCs in vitro and in vivo 50 
Anti-EpCAM (RNA) EpCAM Dox MSNs Inhibit proliferation and induce apoptosis in colon CSCs in vitro 54 
Anti-EpCAM (RNA)  EpCAM Fe-blf AEC-CP Inhibit tumour growth of colon CSCs in vivo 56 
CSC13 (DNA) Prostate CSCs AuNRs CSC13 Induce apoptosis of prostate CSCs in vitro and in vivo 57 
EpDT3 (RNA) EpCAM  Ad5-PTEN EpDT3 Inhibit tumour growth of liver CSCs in vitro and in vivo 63 
EpDT3 (RNA) EpCAM Survivin 
siRNA EpDT3 Reverse chemoresistance of breast CSCs, and inhibit tumour growth in vitro and in vivo 66 
A19 (RNA) EpCAM PLK1 
siRNA A19 Inhibit tumourigenicity of TNBC CSCs and tumour growth in vitro and in vivo 67 
Ep (RNA) EpCAM EpCAM 
siRNA EpApt Inhibit proliferation of RB and breast CSCs in vitro, regresses growth of breast cancer in vivo 68  
Ep (RNA) EpCAM EpCAM 
siRNA PEI NPs Inhibit proliferation of RB and breast cancer CSCs in vitro 69  
EpDT3 (RNA) EpCAM BCL9l SWNT-PEI NPs Induce apoptosis of breast CSCs in vitro 70 
HER-2 apt (DNA) HER-2 MED1 
siRNA pRNA-HER2apt Reduce breast CSCs population and inhibit tumour growth and metastasis in vivo 72 
MRP1 apt (RNA) MRP1 CD28 apt MRP1 apt Enhance anti-tumour immunity to MRP1 melanoma CSCs 87 
 
 
Figure 3. Schematic illustration of drug delivery to CSCs via aptamer-based targeting. The optimal molecular size of aptamer-Dox-PEG conjugate or aptamer-guided 
NPs can facilitate their passive diffusion into the leaky vasculature of tumour tissues based on their enhanced permeability and retention (EPR) effect. Due to the 
impairment of tumour lymphatic drainage, these aptamer-based conjugates can accumulate in the vicinity of the tumour bulk and may selectively penetrate into the 
tumour core (where CSCs reside) via active targeting of aptamers. Aptamer-based conjugates can specifically bind to the surface receptors of CSCs and can be taken 
up by CSCs via receptor-mediated endocytosis. Following internalization and escape from endosomes, the released drugs engage their cytoplasmic or nucleic targets 
to destroy CSCs. 
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Application of aptamers in the delivery of free 
drug to CSCs 
Both DNA and RNA aptamers are known to 
form tertiary structures that contain short double 
stranded regions through intra-molecule base pairing. 
Chemotherapeutic agents such as Dox can be 
preferably inserted into the GC pairs of the double 
strand domain of aptamers through non-covalent 
intercalation to generate a therapeutic conjugate. 
Utilizing this physical conjugation method, a chimeric 
EpCAM aptamer-Dox conjugate was found to 
specifically deliver Dox to EpCAM+
 
retinoblastoma 
CSCs and to selectively inhibit proliferation [46]. 
Similarly, a DNA aptamer against a putative leukemia 
CSC marker CD117 was conjugated with 
methotrexate (MTX). The resultant CD117 apt-MTX 
complex could be selectively taken up and 
internalized to CD117+
 
AML cells, leading to potent 
inhibition of tumour growth [44]. However, the weak 
non-covalent connection between drug and aptamer 
makes drug encapsulation and uptake efficiency 
unpredictable. Moreover, these conjugates with small 
physical size are also flawed by rapid renal clearance 
and inefficient drug retention due to lack of a 
sustainable drug release system [47].  
Application of aptamers in the delivery of 
nanoparticle (NP)-based drugs to CSCs  
Nano-materials that have superior drug 
encapsulation and controllable drug release capacity 
have proved to be more effective and safer for 
anti-CSC therapy. NPs including organic polymers 
such as poly lactic-co-glycolic acid (PLGA) and 
inorganic NPs have been loaded with therapeutic 
agents and linked with long-living aptamers specific 
to unique surface markers of CSCs. These 
aptamer-guided NP systems enhance the selective 
uptake and retention of therapeutic drugs within 
tumours, achieving promising and specific 
CSC-killing.  
Delivery of organic nanoparticle (NP) drugs to 
CSCs 
Liposomes are one of the most successful 
NP-based drug delivery tools due to advantages such 
as high biocompatibility and stability, ease of 
synthesis and low toxicity. PEGylated liposomal Dox 
was the first FDA approved NP-based drug. In a 
recent study, PEGylated liposomal NPs were 
prepared by modifying them with aptamers against 
the CSC marker CD44. The resultant 
aptamer-liposome complex demonstrated high 
selectivity and affinity to CD44+
 
lung CSCs [39]. 
However, such a liposomal formulation could not 
provide continuous release of loaded drugs, leading 
to short drug retention and undesirable in vivo 
therapeutic efficacy [42]. Subsequently, poly (D, 
L-lactide-co-glycolide) (PLGA)-PEG NP have been 
investigated as a more promising approach owing to 
their favourable biocompatibility and sustained drug 
release properties [48]. This nano-scale system is 
composed of PLGA which is able to form a 
hydrophobic core for encapsulating various drugs, a 
PEG shell to the prolong circulating half-life in vivo, 
and aptamers attached on the surface to target CSCs. 
Recently, a RNA aptamer against EpCAM covalently 
coupled to the surface of a PLGA-PEG 
nanopolymersome was successfully loaded with Dox 
with an encapsulation efficiency of more than 90%. In 
this system, Dox could be constantly released from 
the aptamer-NP after the initial burst of release. 
Moreover, the resultant complex exhibited more 
efficient internalization and penetration into tumour 
spheroids resulting in potent selective inhibition in 
the growth of EpCAM+
 
breast cancer in vitro and lung 
cancer both in vitro and in vivo [48, 49]. In another 
study, an anti-EpCAM aptamer conjugated 
PLGA-PEG NP was used to encapsulate curcumin 
(CUR), a natural anti-tumour compound with poor 
solubility and limited bioavailability [36]. In order to 
improve the stability and drug-loading capacity of 
PLGA-PEG, lecithin known as a good dispersing 
agent was coated onto the PEG core. Due to the 
sustainable drug release from the polymer matrix 
after drug absorption, the resultant CUR-NPs 
exhibited an approximately 6-fold increase in half-life 
and a 3-fold increase in mean retention time in vivo 
compared to free CUR. This led to significant 
inhibition of proliferation of EpCAM+
 
colon CSCs in 
vitro and colon cancer growth in vivo [36]. 
Apart from their role in targeted and sustained 
drug delivery, aptamer-guided NPs can be used to 
simultaneously detect cancer cells and assess 
therapeutic response. In this setting, a 
multi-functional nanotheranostic system was 
formulated by conjugating EpCAM aptamers and 
imaging quantum dots (QD) onto the surface of PLGA 
NPs that were pre-loaded with a chemotherapeutic 
agent nutlin-3a (Fig. 4A) [50]. This nutlin-3a-loaded 
apt-QD-PLGA nano-system demonstrated better 
accumulation and deeper penetration into 
QD-visualizing EpCAM+
 
breast and ovarian cancer 
spheroids than the untargeted NPs counterparts and 
showed promising therapeutic effects against 
EpCAM+
 
tumours cells [50]. Although PLGA NPs 
have an encapsulation efficiency of 60~90% 
(percentage of the amount of loaded drug relative to 
total amount of drug used for the formulation), the 
drug incorporation efficiency of PLGA (percentage of 
the amount of the loaded drug relative to the total 
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amount of NPs) is generally unsatisfactory, being 
around 10% [51]. This is mainly attributed to the 
water solubility of hydrophilic drugs which can lead 
to rapid partitioning into the aqueous phase and 
hence decrease their entrapment into NPs during 
polymer deposition [52]. Besides, the large porous 
area of PLGA geometry also contributes to enhanced 
drug leakage into the aqueous phase. The low drug 
incorporation efficiency constitutes a major hurdle for 
commercialization of PLGA-based NPs since a large 
quantity of expensive PLGA with well-defined 
characteristics need to be required to achieve 
desirable drug concentrations at targeted sites [52].  
Delivery of inorganic nanoparticle (NP) drugs 
to CSCs 
In order to overcome the drug leaking issue of 
organic polymer NPs, some inorganic NPs such as 
mesoporous silica NPs (MSNs) have recently been 
developed. MSNs as mesostructures have several 
advantages over polymer NPs including controllable 
configuration, larger surface area and smaller but 
higher organized pore networks. These features 
greatly reduce the leakage of anti- cancer drugs from 
the pore tunnels and increases drug loading capacity 
[53]. Recently, Dox-loaded MSNs were surface 
conjugated with an anti-EpCAM aptamer to 
selectively transport Dox to EpCAM-expressing colon 
cancer cells (Fig. 4B). The resulting apt-MSN-Dox NPs 
showed high Dox incorporation efficiency of 41.6% 
and increased uptake by EpCAM+
 
but not by the 
EpCAM-
 
colon cancer cells leading to more 
cytotoxicity and apoptosis on targeted cells than the 
non-targeted MSN-Dox control [54].  
Iron-saturated bovine lactoferrin (Fe-blf) is a 
multifunctional pleiotropic natural glycoprotein that 
exhibits potent anti-cancer activity in breast, lung, 
bladder, colon and liver cancers [55]. In order to 
overcome the harmful effects of Fe-blf to normal cells 
and further enhance their bioavailability to tumour 
sites, an alginate-enclosed, chitosan-coated (AEC), 
calcium phosphate (Ca-P) inorganic nanocarrier 
(NCs) was formulated to encapsulate Fe-blf and 
surface modified with an EpCAM aptamer (Fig. 4C) 
[56]. The rate of uptake of the modified NCs by the 
EpCAM+
 
cells was 2.84-fold higher than that by the 
EpCAM- cells. Additionally, the resulting 
AEC-CP-Fe-blf-apt nano-formulation was found to 
significantly regress the growth of xenograft tumours 
derived from EpCAM+/CD133+/CD44+
 
colon CSCs in 
mice and to decrease CSCs marker expression. Only 
10% of mice fed with AEC-CP-Fe-blf-apt showed 
tumour recurrence compared to 30% tumour 
recurrence in mice fed on non-targeted NCs [56]. In 
addition to delivering chemotherapeutic payloads to 
CSCs, aptamers have been utilized to selectively 
induce photothermal destruction of CSCs. Previously, 
an aptamer called CSC13 targeting a subpopulation of 
prostate CSCs was conjugated with inorganic gold 
nanorods (AuNRs) and was found to convert 
near-infrared (NIR) laser to localized thermal energy 
resulting in photo- thermal destruction of adjacent 
cells (Fig. 4D) [57]. Upon selective uptake and 
internalization, AuNRs were released from 
CSC13-AuNRs and generated sufficient thermal heat 
enabling a sharp increase of temperature from 25°C to 
55°C in the target cells (prostate CSCs) while the 
temperature of the untargeted cells was barely 
affected. This specific laser-irradiation effect of 
CSC13-AuNRs selectively induced apoptosis of 
prostate CSCs with minimal harmful effect on 
surrounding normal tissues [57]. 
Delivery of nanoparticles (NP) drugs to both 
CSCs and non-CSCs  
Due to the plasticity of CSCs in that non-CSCs 
may dedifferentiate into CSCs in response to 
therapeutic pressure, selectively depleting CSCs 
would not be sufficient to prevent tumour recurrence 
if the residual differentiated non-CSCs are still 
present. Hence, more effective therapeutic approaches 
targeting both CSCs and non-CSCs is essential. One of 
the plausible approaches would be to utilize aptamers 
targeting common receptors that are overexpressed in 
both tumour bulk cells and CSCs. For example, 
epidermal growth factor receptor (EGFR) is known to 
be over-expressed in the majority of tumour cells and 
CSCs of breast, brain and pancreatic cancers [58]. In 
previous studies, cetuximab (an EGFR-specific 
antibody) was used as a targeting agent to specifically 
deliver gold NPs loaded with gemcitabine (GEM) to 
pancreatic cancer cells and achieve significant 
inhibitory effects on tumour growth in vivo [59]. In 
order to attenuate the severe toxicities of cetuximab, 
another group subsequently utilized a RNA aptamer 
against EGFR (E07) to escort GEM to pancreatic 
cancer cells. GEM as a nucleoside analog was 
incorporated into the selection oligonucleotide pool 
and annealed to the EGFR aptamer to create a nucleic 
acid compound with two functional domains 
composed of EGFR aptamer and GEM-containing 
polymer [60]. The E07-GEM polymer exhibited 
selective internalization to EGFR+
 
cells and stronger 
inhibitory effects on EGFR+
 
pancreatic cells in vitro 
than the non-escorted GEM polymer [60]. In addition, 
a new DNA aptamer (HB5) against HER2 
(over-expressed in both differentiated breast cancer 
cells and breast CSCs) was shown to specifically carry 
Dox into HER2+
 
breast cancer cells and selectively 
regress tumour growth in vitro [61, 62].  
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Aptamer-guided delivery of therapeutic 
nucleic acids to CSCs  
Apart from delivering poorly soluble drugs, 
aptamers can be used to selectively transport tumour 
suppressor gene to CSCs. For example, a recombinant 
adenovirus coupling the tumour suppressor gene 
PTEN (Ad5-PTEN) was shown to be an effective 
anti-tumour agent for liver cancer [63]. Through 
conjugating with EpCAM aptamer (EpDT3) and PEG, 
the serum retention of Ad5-PTEN could be increased 
16-fold resulting in a significant inhibition of tumour 
growth in vitro and in vivo of EpCAM-positive liver 
cancer [63]. SiRNA and miRNA which function as 
crucial post-transcriptional suppressors of target 
genes via RNA interference (RNAi) can knockdown 
vital oncogenic and anti-apoptotic genes that are 
involved in drug resistance of CSCs [64]. However, 
clinical application of therapeutic siRNA and miRNA 
is limited by several shortcomings such as low cellular 
uptake, poor pharmacokinetic profiles and systemic 
toxicity due to their nuclease-labile and hydrophilic 
characteristics [65]. Thus, more efficient 
aptamer-based delivery systems that can protect 
siRNAs and miRNAs from nuclease degradation and 
facilitate their selective intracellular transport and 
accumulation in tumour cores to target CSCs are 
needed (Table 3). Currently several aptamers against 
CSC surface markers have been developed to achieve 
specific siRNA and miRNA delivery to CSCs of 
various tumours (Fig. 5).  
Aptamer-guided delivery of siRNAs to CSCs 
Survivin is an important pro-survival protein 
involved in the promotion of tumour angiogenesis 
and chemo-resistance. An EpCAM-specific aptamer 
has been utilized to specifically deliver survivin 
siRNAs to breast CSCs leading to a decrease of 
endogenous survivin by more than 80% in EpCAM+
 
breast cancer cells [66]. Moreover, this 
aptamer-siRNA chimera-mediated survivin silencing 
reversed chemo-resistance such that combined 
treatment with Dox significantly inhibited tumour 
growth and prolonged survival of mice bearing 
chemo-resistance tumours accompanied by the 
reduction of CSC populations and impairment of 
self-renewal capacity [66]. In another interesting 
example, an EpCAM aptamer-siRNA chimera known 
as AsiC was used to specifically deliver polo like 
kinase 1 (PLK1) siRNA to triple-negative breast cancer 
(TNBC, which are poorly differentiated breast cancers 
lacking the expression of estrogen, progesterone and 
HER2 receptors). In the AsiC chimera, the EpCAM 
aptamer was connected to the PLK1 siRNA sense 
strand via a U-U-U linker and then annealed to the 
anti-sense strand of siRNA. This PLK1 EpCAM-AsiC 
could efficiently knockdown PLK1 expression and 
significantly attenuated the tumour initiating and 
self-renewal ability of EpCAM+
 
TNBC CSCs in vitro, 
and regressed the growth of xenograft tumours 
derived from EpCAM+
 
but not EpCAM- TNBCs [67].  
 
 
Figure 4. Schematic illustration of aptamer-based NPs. A. Structure of aptamer-Nut-QD-PLGA- PEG NPs. B. Structure of aptamer-Dox-MSNs NPs. C. Structure 
of aptamer-alginate-chirosan-Ca- Fe-blf NPs. D. Structure of aptamer-AuNRs NPs. 
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Figure 5. Schematic illustration of aptamer-mediated nucleic acid delivery to CSCs. Exogenous therapeutic siRNAs or miRNAs can be directly linked with aptamers 
or encapsulated within NPs that is surface functionalized with aptamers. Aptamer-siRNA/miRNA or aptamer-NPs can bind to and internalize into CSCs via 
receptor-mediated endocytosis, followed by entry into the endosome complex. Under the acidic environment, siRNAs/miRNAs are released and escape from 
endosomes and are then incorporated into the RNA-induced silencing complex. The mature siRNAs and most miRNAs interact with their cytoplasmic target mRNA 
while a few miRNAs such as miR29b are predominantly localized to nuclei, leading to mRNA degradation, translational and transcriptional regulation. 
 
EpCAM is not only a well-known CSC marker 
but also an important transcriptional target of 
oncogenic Wnt/β-catenin signalling. EpCAM can be 
cleaved by a tumour-necrosis-factor alpha converting 
enzyme (TACE/ADAM17) leading to the release of an 
intracellular domain (EpICD) of EpCAM into the 
cytoplasm. EpICD can migrate into the nucleus where 
it forms a complex with four and a half LIM domain 2 
(FHL2), β-catenin and lymphoid enhancer binding 
factor 1 (Lef1). This complex in turn induces the 
activation of target genes (such as c-myc and cyclins) 
of Wnt/β-catenin signalling [68]. In a recent study, an 
EpCAM aptamer was coupled with siRNA against 
EpCAM and the resulting chimera (EpApt-siEp) 
successfully knocked down EpICD expression in 
EpCAM+
 
cancer cells [68]. Moreover, this chimera was 
shown to significantly and specifically inhibit the 
proliferation of EpCAM+
 
retinoblastoma (RB) cells 
and epithelial breast cancer cells in vitro, and 
completely regress the growth of epithelial breast 
cancer in vivo [68]. In order to improve the stability 
and tumour retention of the therapeutic EpCAM 
siRNA, the same group further incorporated siRNA 
into a cationic PEI polymeric carrier that was surface 
coupled with the EpCAM aptamer. The resulting 
PEI-EpApt-SiEp nano-complex selectively silenced 
EpCAM expression and exerted stronger 
anti-proliferative effects than EpApt-siEp to EpCAM+
 
RB cells and breast cancer cells in vitro [69].  
Another recently synthesized single-walled 
carbon nanotube (SWNT) with a unique nano-needle 
structure was shown to efficiently cross the plasma 
 Theranostics 2017, Vol. 7, Issue 16 
 
 
http://www.thno.org 
3958 
membrane by an endocytosis-dependent pathway 
[70]. To overcome the poor solubility and low 
biocompatibility of SWNT, SWNT was conjugated to 
a hydrophobic piperazine-PEI derivative that was 
surface linked with an anti-EpCAM aptamer (EpDT3) 
for specific delivery of siRNA against B cell 
lymphoma 9-like (BCL9L), an oncogene required for 
Wnt activation. This SWNT-PEI-EpDT3 nano- 
complex exhibited 10-fold higher siRNA delivery 
efficiency than PEI alone in EpCAM+
 
breast cancer 
cells. Consequently, efficient silencing of BCL9L 
specifically induced significant apoptosis in EpCAM+
 
breast cancer cells [70]. 
Due to the high plasticity of CSCs, delivering 
therapeutic nucleic acids to both differentiated and 
undifferentiated tumour cells (CSCs) would be a 
desirable approach for cancer therapy. In this regard, 
aptamers targeting the HER-2 gene have been 
employed as the delivery vehicle of siRNA against an 
anti-apoptotic gene, B cell lymphoma 2 (BCL-2). This 
aptamer-conjugated BCL-2 siRNA effectively 
increased the chemo-sensitivity of HER-2+
 
breast 
cancer cells to cisplatin-induced apoptosis [71]. 
Another recent study generated a novel 
multifunctional RNA NP using the three-way junction 
(3WJ) motif derived from bacteriophage phi29 
packaging RNA (pRNA) as the scaffold core [72]. The 
pRNA NPs were further coupled with a HER2 
aptamer and siRNA against estrogen receptor (ER) 
coactivator mediator subunit 1 (MED1) to form a 
pRNA-HER2apt-siMED1 complex. In addition to their 
capacity to significantly reduce tumour growth and 
metastasis, the resulting complex greatly depleted 
CSCs of HER2-expressing breast tumour when 
combined with tamoxifen treatment in vivo [72]. 
Although a direct effect on CSC fate has not been 
claimed, the anti-tumour effects from these 
proof-of-concept studies indicates a novel direction in 
aptamer-based delivery of chemo-sensitizing siRNAs 
to cancer cells.  
Aptamer-guided delivery of miRNAs to CSCs 
miRNAs have been demonstrated to play both 
oncogenic and tumour suppressive roles and are a key 
regulatory factor in the treatment resistance of CSCs 
[73]. To this end, specific delivery of tumour- 
suppressive miRNA such as miRNA126 and 
miRNA34 to CSCs through aptamer-based 
approaches may represent a promising therapeutic 
strategy [10]. 
Transferrin receptor (TfR) is overexpressed on 
both CSCs and non-CSCs of various cancers including 
those from lung, breast, brain and pancreas [74]. 
Recently, a TfR-specific aptamer which elongated at 
the 3’ end with the passenger strand of the siRNA 
sequence via a GC-rich “stick” complementary linker 
and further annealed to a guide strand of siRNA was 
developed. Such sticky-end annealing linkage not 
only ensures correct folding of the aptamers, but also 
reinforces the non-covalent binding between the 
miRNA and the aptamer [75]. Based on this approach, 
the TfR aptamer was shown to specifically deliver 
tumour suppressor miR126 into breast cancer cells 
leading to a significant inhibition of cell proliferation 
in vitro [76]. In a similar report, tumour suppressor 
miR222 was delivered into PDGF+ glioblastoma 
(GBM) cells by Gint 4.T, an aptamer against platelet 
derived growth factor receptor (PDGFR) which is 
extensively expressed in both differentiated tumour 
bulk cells and CSCs, resulting in marked reduction of 
tumour growth in vitro and in vivo [77]. 
In order to increase the retention and stability of 
therapeutic miRNAs in the circulation, 
aptamer-conjugated nano-carriers that can 
sustainably release encapsulated miRNAs into 
desired tumour sites have been exploited. For 
instance, polyamidoamine (PAMAM) that is cationic 
with dendritic structures are widely employed as 
non-viral gene vectors to transfect exogenous DNA or 
RNA into cells. In a recent study, PAMAM-PEG NPs 
were utilized to efficiently encapsulate miR34a (a 
potent endogenous tumour suppressor), and the 
miR34a-encapsulated NPs were conjugated with S6, 
an aptamer against A549 lung cancer cells. The 
resulting chimera (PAM-Ap/pMiR-34a NPs) was 
shown to inhibit the growth and migration of lung 
cancer cells [78]. In another report, a novel 
multifunctional RNA NP was generated using the 
three-way junction (3WJ) motif [74]. This pRNA-3WJ 
core was further modified to form trifunctional NPs 
harboring three functional modules including EGFR 
aptamers as the targeting ligand to TNBC, therapeutic 
anti-miR-21, and Alexa-647 as an imaging module 
[79]. The resultant chimera 3WJ-EGFRapt/anti- 
miR-21 was shown to successfully navigate across the 
tumour micro-environment barriers, significantly 
down-regulating oncogenic miRNA-21 and 
up-regulating its down-stream targets such as tumour 
suppressor phosphatase and tensin homolog (PTEN) 
and programmed cell death 4 (PDCD4), resulting in 
efficient eradication of TNBC CSCs and inhibition of 
tumour growth both in vitro and in vivo [79].  
Aptamer-guided co-delivery of 
therapeutics to CSCs  
As multiple mechanisms are involved in the 
development of drug resistance of CSCs, blocking one 
mechanism with a single anti-cancer agent frequently 
activates and strengthens alternative pathways 
leading to ongoing drug resistance and tumour 
 Theranostics 2017, Vol. 7, Issue 16 
 
 
http://www.thno.org 
3959 
relapse [57]. Therefore, approaches that target 
multiple mechanisms such as co-administration of 
drug cocktails or combined drug and nucleic acid 
therapy may exert synergistic inhibitory effects on 
CSCs. Previously, multi-functional NP systems such 
as PLGA-PEG, liposomes and micelles that can 
simultaneously incorporate multiple therapeutic 
agents into a single NP have been investigated. These 
therapeutic complexes are specifically delivered into 
tumour cells under the guidance of targeting aptamer 
moieties with promising therapeutic efficacy [80-82]. 
However, most of these studies were only tested in 
vitro and whether these multifunctional aptamer-NPs 
can improve specific cytotoxicity to CSCs and regress 
tumour re-growth is still unknown. In order to 
achieve the best possible therapeutic effect, 
development of smart aptamer-coupled nano-carriers 
that can selectively deliver drug combinations to 
CSCs and comprehensively evaluating their 
CSC-targeting efficacy is necessary. 
Aptamer-guided delivery of 
immunotherapeutic drugs to CSCs 
The interaction of co-stimulatory molecules 
(such as 4-1BB, CD28 and OX40) with their cognate 
ligands is essential for the activation of T lymphocytes 
[83]. The reduction of co-stimulatory ligands within 
the tumour microenvironment greatly compromise 
the ability of T cells to exert anti-tumour immunity 
[83]. Some agonistic aptamers against CD28 and 4-1 
BB were found to co-stimulate T cells and promote 
tumour immunity [84, 85]. To minimize the 
non-specific targeting of these agonists, a bi-specific 
aptamer that can simultaneously target prostate 
specific membrane antigen (PSMA) and the 4-1 BB 
receptor was developed and shown to potentiate 
T-cell dependent tumour immunity at prostate 
tumour sites [86]. However, the effects of these 
co-stimulatory aptamers on CSCs are poorly 
understood. In this regard, a new multidrug 
resistance-associated protein 1 (MRP1) aptamer 
targeting chemotherapy-resistant melanoma CSCs 
was first developed and utilised to form a new 
bi-specific MRP1-CD28 aptamer [87]. The resulting 
bivalent aptamer was able to specifically deliver the 
protective CD28 co-stimulatory signals to 
MRP1-expressing melanoma CSCs eliciting a potent 
anti-tumour immune response and reduced tumour 
growth in vivo than conventional CD28 agonist [87]. 
Moreover, a whole-cell vaccine (aptvax) consisting of 
irritated melanoma tumour cells coated with 
MRP1-CD28 aptamer was shown to boost 
anti-tumour immunity and significantly inhibit 
tumour growth in vivo [87]. 
Conclusions and challenges  
It is now well-accepted that the evolution of 
cancer follows Darwin's principle of “survival of the 
fittest”, uncovering the unique competitiveness and 
aggressive nature of CSCs in adapting to the 
pressures of cancer treatment. Moreover, CSCs within 
a heterogeneous tumour displays complex plasticity 
by reversibly transitioning between CSCs and 
differentiated cancer cells. The tumour- initiating and 
chemo-resistant capabilities of CSCs neccesitate the 
development of effective anti-CSC therapeutic 
strategies that can selectively destroy resistant CSCs. 
Through the combination of anti-CSCs and traditional 
therapeutic approaches, both residual tumour cells 
and CSCs are more likely to be depleted, avoiding the 
frequent switching of non-CSCs to CSCs and tumour 
relapse. To achieve these goals, a number of NP 
systems have been incorporated with specific 
aptamers targeting CSC surface markers and has 
demonstrated promising therapeutic efficacy for 
CSCs in pre-clinical studies.  
However, several key problems need to be 
resolved before aptamer-NP conjugates can be widely 
tested in clinical settings. First, there is a lack of a 
specific marker for CSCs and the currently available 
markers for CSCs are also present on normal stem 
cells and even normal cells. Therefore, 
aptamer-nano-carriers aimed at targeting CSCs may 
exert non-specific toxicity to normal stem cells. One 
potential and feasible approach is to develop 
aptamers that specifically target stemness-enriched 
cancer cells (such as tumour sphere cells generated 
from patients-derived tumour cells) rather than CSC 
markers using the whole-cell SELEX method. To 
select unique CSC-specific aptamers, the living 
tumour sphere cells are utilised as targets and 
negative selection is performed using normal cancer 
cells to eliminate non-CSC associated aptamers. This 
was exemplified by a very recent study that 
developed two pancreatic CSC-associated DNA 
aptamers using tumour sphere cells as targets in the 
Cell-SELEX selection [88]. Second, the tumour 
penetration potential of aptamer-guided conjugates 
has mostly been tested in in vitro studies but rarely in 
relevant animal models. Whether aptamer-based drug 
delivery actually facilitates drug accumulation and 
release into the deep layers of tumours is still unclear. 
Therefore, comprehensive evaluation of tumour- 
penetrating and cargo-delivering characteristics of 
aptamer-targeted conjugates in vivo using living 
animal imaging systems is necessary in future studies. 
Third, in most studies, the approach for evaluating 
the therapeutic efficacy of anti-CSC therapies in 
preclinical models is based on tumour volume 
reduction. However, tumour eradication and 
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prevention of tumour relapse that genuinely reflects 
an effect on CSC elimination has rarely been assessed. 
In this aspect, developing clinically-relevant mouse 
models (such as patient-derived orthotopic models) 
that can not only closely recapitulate the pathologic 
tumour microenvironment but can also mimic tumour 
metastasis and regrowth may be a viable approach to 
precisely assess the therapeutic efficacy of anti-CSC 
agents. In conclusion, although aptamer-mediated 
anti-CSC therapy provides a promising strategy to 
eliminate the “culprit” of cancers, more robust 
pre-clinical and clinical studies are needed to explore 
their full therapeutic potential. 
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